Peptide Clinical Trials 2026: What's in the Pipeline

Peptide therapeutics have moved from niche research curiosity to one of the most active drug development categories in modern medicine. The success of GLP-1 receptor agonists like semaglutide and tirzepatide has convinced pharmaceutical companies and investors alike that peptides can generate blockbuster revenues — and that pressure is now accelerating trials across virtually every therapeutic area.

This overview covers the most significant peptide clinical trials underway as of 2026, organized by development phase and therapeutic category. Whether you're a researcher, clinician, or someone closely following the field, these are the candidates worth watching.

Why Peptide Drug Development Has Accelerated

Several converging factors explain why the peptide pipeline is more robust today than at any prior point in pharmaceutical history.

The GLP-1 success story demonstrated that peptides could achieve systemic metabolic effects that small molecules simply cannot replicate. Tirzepatide's dual GIP/GLP-1 agonism producing greater weight loss than any prior approved therapy proved that multi-receptor peptide strategies work in humans — and that regulatory agencies will approve them relatively quickly when the efficacy data is compelling.

Simultaneously, manufacturing has improved. Solid-phase peptide synthesis at commercial scale is cheaper and more reliable than it was a decade ago. This makes it economically feasible to run larger trials with more patients. Formulation science has also advanced: long-acting peptide formulations using PEGylation, depot injection, and fatty acid conjugation now allow weekly or even monthly dosing, which dramatically improves trial compliance and patient convenience.

Finally, AI-accelerated discovery is feeding novel candidates into the pipeline faster than before. AI and peptide discovery tools can now screen billions of sequence variants in silico, flagging candidates with favorable binding profiles before a single animal study begins.

Phase III: Candidates Near Approval

Retatrutide (Triple GIP/GLP-1/Glucagon Agonist)

Eli Lilly's retatrutide targets three receptors simultaneously — GIP, GLP-1, and glucagon — producing weight loss results that exceeded tirzepatide in head-to-head animal studies. Phase III trials in adults with obesity and type 2 diabetes are ongoing, with primary endpoints around 72 weeks of treatment. Interim data has shown mean weight loss exceeding 24% from baseline in the highest-dose cohorts, a number that would represent a new benchmark for pharmacological obesity treatment.

Cagrilintide + Semaglutide (CagriSema)

Novo Nordisk's combination of cagrilintide (an amylin analogue) with semaglutide demonstrated 25%+ weight reduction in Phase II, prompting rapid advancement to Phase III. Amylin slows gastric emptying and promotes satiety through pathways distinct from GLP-1, making this combination mechanistically additive. The REDEFINE trial program is expected to complete enrollment through 2026.

Oral Semaglutide for Cardiovascular Risk Reduction

Having already gained approval for type 2 diabetes management, oral semaglutide is now in Phase III trials specifically for cardiovascular endpoints in non-diabetic, high-risk populations. The SOUL trial data, published in 2025, showed significant reductions in major adverse cardiovascular events. Follow-on studies are now examining dosing optimization for this indication.

Phase II: Compelling Mid-Stage Data

Maritide (AMG 133 — GLP-1/GIPR Antagonist)

Amgen's maritide takes a counterintuitive approach to GIPR: rather than agonizing GIP receptors (as tirzepatide does), it antagonizes them. Early data suggests this strategy may yield comparable weight loss with a different side-effect profile. Phase II data is expected in late 2026, and the mechanistic novelty makes it one of the more scientifically interesting candidates in the pipeline.

BMP-7 Analogues for Chronic Kidney Disease

Bone morphogenetic protein 7 analogues are in Phase II trials for chronic kidney disease — specifically targeting renal fibrosis pathways. Early signals show reductions in urinary biomarkers of fibrosis progression. This represents an entirely different therapeutic category from metabolic peptides, illustrating how broad the pipeline has become.

Peptide-Based GLP-1/Neuropeptide Y Dual Agonists for Addiction

Several academic spinouts are in Phase II with peptides targeting both GLP-1 and neuropeptide Y receptors in the central nervous system. GLP-1 receptors are expressed in reward circuitry, and early data suggests GLP-1 agonists may reduce cravings for alcohol and opioids. These trials are among the most scientifically novel in the current pipeline. Related research on peptides for PTSD has explored overlapping CNS mechanisms.

Thymosin Alpha-1 for Long COVID

Thymosin alpha-1, an immunomodulatory peptide already approved in several countries for hepatitis and cancer adjunct therapy, is in Phase II trials in multiple countries for long COVID immune dysregulation. The hypothesis is that thymosin alpha-1 can help re-regulate immune function in patients with persistent inflammatory symptoms.

Phase I: Early-Stage Candidates

De Novo AI-Designed Antimicrobial Peptides

At least three companies — Absci, Generate Biomedicines, and Peptone — have advanced AI-designed antimicrobial peptides into Phase I trials. These candidates were designed entirely computationally, with no natural peptide template, representing a genuine milestone in AI-assisted drug discovery.

Peptide-PD-1 Inhibitor Conjugates for Solid Tumors

Tumor-homing peptides conjugated to checkpoint inhibitor payloads are entering Phase I for several solid tumor indications. The rationale: concentrate checkpoint blockade at the tumor site to reduce systemic immune activation. These are peptide-drug conjugates that extend the ADC concept into immunotherapy.

Oral GLP-1 Analogues with Novel Permeation Enhancers

Beyond semaglutide, several companies are testing entirely new peptide backbones optimized for oral delivery. These Phase I trials are primarily safety and pharmacokinetic studies focused on demonstrating bioavailability rather than efficacy.

Oncology Peptide Trials: A Growing Sector

Peptide vaccines represent one of the most active areas of oncology clinical development. Neoantigen peptide vaccines — personalized to each patient's tumor mutation profile — are in Phase I/II at dozens of institutions. BioNTech, Moderna, and Gritstone Bio all have active trials combining personalized peptide neoantigens with checkpoint inhibitors.

Radiolabeled peptides for imaging and therapy (theranostics) are also advancing rapidly. PSMA-targeting peptides conjugated to lutetium-177 gained FDA approval for metastatic prostate cancer, and multiple follow-on peptide radiopharmaceuticals are in Phase I and II.

Regulatory Environment in 2026

The FDA has issued updated guidance on peptide drug products, clarifying manufacturing standards and the regulatory pathway for peptide therapeutics above the traditional small-molecule cutoff. The guidance acknowledges that the line between peptide and biologic is increasingly blurred, especially for longer synthetic peptides and peptide-Fc fusion proteins.

In Europe, the EMA is developing specific guidelines for peptide-drug conjugates following the clinical success of early ADC candidates, and these will apply equally to peptide-linker-payload constructs.

One important note: the peptide legal landscape continues to evolve as more candidates transition from research chemical status to IND and NDA filing. The filing of an IND by any company doesn't automatically restrict researcher access, but it can trigger scheduling discussions.

What to Watch in Late 2026

The REDEFINE trial readout for CagriSema, retatrutide's Phase III primary endpoint data, and the first Phase II results from AI-designed antimicrobial peptides are all expected in the second half of 2026. These readouts will substantially shape investment and development priorities for 2027 and beyond.

The pipeline is broader, more scientifically sophisticated, and better capitalized than at any prior point in peptide medicine history. The question is no longer whether peptides can produce transformative drugs — the evidence for that is already in hand — but rather which mechanisms, delivery formats, and therapeutic areas will define the next decade of approvals.

Frequently Asked Questions

Q: How many peptide drugs are currently approved by the FDA? As of 2026, over 80 peptide-based drugs are approved by the FDA across various therapeutic areas, including insulin analogues, GLP-1 agonists, and antimicrobial peptides. The number has grown substantially in the last five years.

Q: What is the difference between a Phase I, Phase II, and Phase III clinical trial? Phase I trials primarily assess safety and dosing in small groups (typically 20–100 participants). Phase II trials evaluate efficacy and side effects in larger groups (100–300). Phase III trials confirm efficacy, monitor adverse reactions, and compare to existing treatments in large populations (1,000+) before regulatory submission.

Q: Are GLP-1 peptides still in clinical trials if they're already approved? Yes. Approved compounds like semaglutide continue to be studied in new indications (cardiovascular disease, liver disease, addiction, neurodegeneration) while the original indications remain in use. Post-approval trials are common and often lead to new label expansions.

Q: Can I participate in a peptide clinical trial? ClinicalTrials.gov lists all registered trials in the US. Eligibility depends on the specific trial's inclusion and exclusion criteria, which typically involve age, BMI, existing conditions, and current medications. Your physician can help determine whether you qualify for any open trials.

Q: Why do so many peptide trials fail after promising preclinical data? The gap between animal and human biology is substantial. Peptides that work dramatically in rodents often face issues in humans related to off-target effects, immunogenicity, dosing, or bioavailability. The ACE-031 story — halted after showing excellent preclinical results — is a well-documented example. This is a challenge across all drug development, not unique to peptides.